# EDGAR Filing Document

**Accession Number:** 0001557860
**File Stem:** 0001104659-26-036220
**Filing Date:** 2026-3
**Character Count:** 50220
**Document Hash:** 91000610662661a91714d5e265e03455
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-26-036220.hdr.sgml**: 20260327

**ACCESSION NUMBER**: 0001104659-26-036220

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 7

**CONFORMED PERIOD OF REPORT**: 20260327

**FILED AS OF DATE**: 20260327

**DATE AS OF CHANGE**: 20260327

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Globant S.A.
- **CENTRAL INDEX KEY:** 0001557860
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-COMPUTER PROCESSING & DATA PREPARATION [7374]
- **ORGANIZATION NAME:** 06 Technology
- **EIN:** 000000000
- **STATE OF INCORPORATION:** U3

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36535
- **FILM NUMBER:** 26808420

**BUSINESS ADDRESS:**
- **STREET 1:** 37A AVENUE J.F. KENNEDY
- **CITY:** N/A
- **STATE:** N4
- **ZIP:** L-1855
- **BUSINESS PHONE:** 35 220301596

**MAIL ADDRESS:**
- **STREET 1:** 37A AVENUE J.F. KENNEDY
- **CITY:** N/A
- **STATE:** N4
- **ZIP:** L-1855

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**

**PURSUANT TO RULE 13a-16 OR 15d-16**

**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**For the month of March 2026**

**Commission File Number 001-36535**

**GLOBANT S.A.**

(Translation of registrant's name into English)

**37A, Avenue J.F. Kennedy<br> L-1855, Luxembourg <br> Tel: + 352 20 30 15 96**

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

⌧ Form 20-F ◻ Form 40-F

**GLOBANT S.A.**

**FORM 6-K**

***Annual General Meeting***

Globant S.A. (the "**Company**") announced that its Annual General Meeting of Shareholders (the "**General Meeting**") is to be held on April 28, 2026. The General Meeting will be held at the registered office of the Company at 37A, Avenue J.F. Kennedy, L-1855, Luxembourg. The record date for the determination of shareholders entitled to vote at the General Meeting is March 27, 2026. The convening notice containing the agenda for the General Meeting and the form of proxy for use in connection with the General Meeting are attached as Exhibit 99.1 hereto.

***Exhibits***

Globant S.A. is furnishing under the cover of Form 6-K the following:

 ****

[<u>Exhibit 99.1</u>](tm2610084d1_ex99-1.htm) [Convening notice containing the agenda, dated March 27, 2026, and form of proxy for the General Meeting to be held on April 28, 2026.](tm2610084d1_ex99-1.htm)

The information contained in this report on Form 6-K, including the documents attached as Exhibit 99.1 to this report on Form 6-K, is hereby incorporated by reference into the Company's registration statements on [Form F-3 (File No. 333-286306)](https://www.sec.gov/Archives/edgar/data/1557860/000110465925030567/tm2431187d1_f3asr.htm) and on Form S-8 (File Nos. [333-201602](https://www.sec.gov/Archives/edgar/data/1557860/000114420415002748/v398985_s8.htm), [333-211835](https://www.sec.gov/Archives/edgar/data/1557860/000114420416106796/v441524_s8.htm), [333-232022](https://www.sec.gov/Archives/edgar/data/1557860/000114420419030304/tv523008_s8.htm), [333-255113](https://www.sec.gov/Archives/edgar/data/1557860/000110465921047710/tm2112188d1_s8.htm), [333-266204](https://www.sec.gov/Archives/edgar/data/1557860/000110465922080573/tm2220944d1_s8.htm) and [333-281049](https://www.sec.gov/Archives/edgar/data/1557860/000110465924083027/tm2419397d1_s8.htm)), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

**Signatures**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | |
|:---|:---|
| **GLOBANT S.A.** | **GLOBANT S.A.** |
| By: | /s/ PATRICIO PABLO ROJO |
|  | Name: Patricio Pablo Rojo |
|  | Title: General Counsel |

---

Date: March 27, 2026

## Exhibit 99.1

**Exhibit 99.1**

![](tm2610084d1_ex99-1img001.jpg)

Dear Shareholders,

I am pleased to inform you that the Annual General Meeting of Shareholders of **Globant S.A.** (the "**Company**") will be held on April 28, 2026, at 16.00 Luxembourg Time, at the registered office of the Company (37A, Avenue J.F. Kennedy, L-1855, Luxembourg).

Because the Company is a Luxembourg company, its affairs are governed by the provisions of the laws of Luxembourg (the "**Luxembourg Laws**"). Under the provisions of the Luxembourg Laws, the Company's accounts for the financial year ended December 31, 2025 must be submitted to shareholders on a consolidated basis under international financial reporting standards as endorsed by the European Union ("**EU IFRS**") and on an unconsolidated basis in accordance with the generally accepted accounting principles of Luxembourg ("**Lux GAAP**"). Further, because the Company's common shares are listed and admitted to trading in the New York Stock Exchange, the accounts for the financial year ended December 31, 2025 have also been prepared on a consolidated basis in accordance with international financial reporting standards ("**IFRS**").

Enclosed with this mailing are the convening notice to the Annual General Meeting of Shareholders and a proxy card relating thereto. If you hold your shares directly in your name in the shareholders' register kept by the Company's transfer agent, please promptly sign, date and return the enclosed proxy card so that your shares can be voted at the Annual General Meeting of Shareholders. If you hold your shares through a brokerage account, please promptly submit your votes as instructed by your broker.

I recommend you vote as suggested by respectively the Board of Directors, the Corporate Governance and Nominating Committee, the Audit Committee and the Compensation Committee of the Company. All voting recommendations made by the Board of Directors and/or the Committees are set forth in the enclosed convening notice under each item of the agenda.

Sincerely,

---

| |
|:---|
| /s/ Martin Migoya |
| Martin Migoya |
| Chairman of the Board of Directors |

---

March 27, 2026

**GLOBANT S.A.**

*société anonyme*

37A, Avenue J.F. Kennedy,

L-1855, Luxembourg

R.C.S. Luxembourg B 173727

("**Globant**" or the "**Company**")

&nbsp;&nbsp; **CONVENING NOTICE TO THE**<br> **ANNUAL GENERAL MEETING OF SHAREHOLDERS**<br> **TO BE HELD ON APRIL 28, 2026 AT THE REGISTERED OFFICE OF THE COMPANY.**<br>

Dear Shareholders,

The Board of Directors of the Company (the "**Board of Directors**") is pleased to invite you to attend the Annual General Meeting of Shareholders of the Company to be held on April 28, 2026, at 16.00 Luxembourg time, at the registered office of the Company (37A, Avenue J.F. Kennedy, L-1855, Luxembourg).

The agenda of the meeting is the following:

**<u>AGENDA OF THE ANNUAL GENERAL MEETING OF SHAREHOLDERS,</u>**

**<u>PROPOSED RESOLUTIONS AND RECOMMENDATIONS.</u>**

**1. Presentation of the reports of the independent auditor and of the reports of the Board of Directors of the Company on the consolidated accounts for the financial year ended on December 31, 2025 and on the annual accounts of the Company for the financial year ended on December 31, 2025.**

No vote is required on this item of the agenda.

**2. Approval of the consolidated accounts of the Company prepared under EU IFRS and IFRS as of and for the financial year ended December 31, 2025.**

Draft resolution (Resolution I)

*"The general meeting, after having reviewed the management report of the Board of Directors and the report of the independent auditor of the Company, approves the consolidated accounts of the Company prepared under EU IFRS and IFRS as of and for the financial year ended on December 31, 2025."*

<u>Recommendation:</u>

The Board of Directors recommends a vote **FOR** the approval of the Company's consolidated accounts under EU IFRS and IFRS as of December 31, 2025, after due consideration of the management report and the independent auditor report on each of such consolidated accounts.

**3. Approval of the Company's annual accounts under LUX GAAP as of and for the financial year ended December 31, 2025.**

Draft resolution (Resolution II)

*"The general meeting, after having reviewed the management report of the Board of Directors and the report of the independent auditor of the Company, approves the annual accounts of the Company under Lux GAAP for the financial year ended on December 31, 2025."*

<u>Recommendation:</u>

The Board of Directors recommends a vote **FOR** the approval of the Company's annual accounts under Lux GAAP as of December 31, 2025, after due consideration of the management report and the report from the independent auditor on such annual accounts.

**4. Allocation of results for the financial year ended December 31, 2025.**

Draft resolution (Resolution III)

*"The general meeting acknowledges that the Company has made a loss of USD 9,582,792.49 during the financial year ended on December 31, 2025 and resolves to carry forward this loss of USD 9,582,792.49 to the following financial year".*

<u>Recommendation:</u>

The Board of Directors notes that, at a consolidated level, the Company has made a gain of USD 103,956,201 during the financial year ended on December 31, 2025, and at an individual (stand-alone) level, the Company has made a loss of USD 9,582,792.49 during such same period. The Board of Directors further notes that this loss at an individual (stand-alone) level is primarily attributed to the recognition of intercompany interests, amounting to USD 6,825,088.11.

The Board of Directors also notes that Luxembourg Laws require that Luxembourg companies allocate a minimum of 5% of the annual net income to the legal reserve, after deduction of any losses brought forward, until this reserve equals 10% of the share capital. As the Company has, at an individual (stand-alone) level, cumulated net losses brought from the 2024 fiscal year, there is no allocation of gains made during the 2025 fiscal year to the legal reserve. As of the fiscal year ended December 31, 2025, the legal reserve of the Company amounted to USD 937,315.75.

The Board of Directors recommends a vote **FOR** the allocation of the result from the 2025 fiscal year at an individual (stand-alone) level, as set forth below:

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;Result of the financial year | &nbsp;&nbsp;**USD** | &nbsp;&nbsp;(9582792.49) |
| &nbsp;&nbsp;Allocation to the legal reserve | &nbsp;&nbsp;**/** | &nbsp;&nbsp;/ |
| &nbsp;&nbsp;Distribution of dividends | &nbsp;&nbsp;**/** | &nbsp;&nbsp;/ |
| &nbsp;&nbsp;Result to be carried forward to the following year | &nbsp;&nbsp;**USD** | &nbsp;&nbsp;(9582792.49) |

---

**5. Vote on discharge (*quitus*) of the members of the Board of Directors for the proper exercise of their mandate during the financial year ended December 31, 2025.**

Draft resolution (Resolution IV)

*"The general meeting grants full and total discharge to the members of the Board of Directors for the exercise of their mandates during the financial year ended on December 31, 2025."*

<u>Recommendation:</u>

In accordance with applicable Luxembourg Laws and regulations, the Corporate Governance and Nominating Committee recommends that, upon approval of the Company's annual accounts as of December 31, 2025, all directors who were members of the Board of Directors during the financial year ended on December 31, 2025, be discharged from any liability in connection with the management of the Company's affairs during such year.

The Corporate Governance and Nominating Committee recommends a vote **FOR** the discharge (*quitus*) of the members of the Board of Directors for the proper exercise of their mandate during the financial year ended on December 31, 2025.

**6. Approval of the cash and share-based compensation payable to the non-executive members of the Board of Directors for the financial year ending on December 31, 2026.**

Draft resolutions (Resolution V)

*"The general meeting approves the following mix of cash and share-based compensation payable to each of the non-executive members of the Board of Directors for the financial year 2026:*

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;***Cash Compensation*** | &nbsp;&nbsp;***Share-based Compensation (Value at grant date)*** | &nbsp;&nbsp;***Total Annual Compensation<br> (Cash + Share-based)*** |
| &nbsp;&nbsp;*USD 100,000* | &nbsp;&nbsp;*USD 150,000* | &nbsp;&nbsp;*USD 250,000* |

---

*The share-based compensation shall be granted in the form of restricted stock units under the terms of the Company's 2024 Equity Incentive Plan. Both the cash and share-based compensation shall be paid in quarterly installments, with share-based compensation vesting on the first anniversary of the grant date. The vesting of granted awards shall not be subject to continued service on the Company's Board of Directors and shall not be tied to performance requirements.*

*The general meeting further approves the grant to Mrs. Linda Rottenberg of an additional share-based compensation for her role as lead independent director during the fiscal year ending on December 31, 2026, in the form of an extra number of restricted stock units under the terms of the Company´s 2024 Equity Incentive Plan, with a value at grant date of USD 150,000, to be granted in quarterly installments, and vesting on the first anniversary of the grant date. The vesting of granted awards will be subject to the continuous service of the lead independent director through the vesting date."*

<u>Recommendation</u>

In accordance with the charter of the Compensation Committee adopted by the Board of Directors, the Compensation Committee is tasked with, among other functions, setting compensation for the directors of the Company.

After careful review and consideration, the Compensation Committee deems it advisable and proposes to maintain the same mix of cash and share-based compensation paid to the Company's non-executive directors for the 2025 financial year, and therefore pay the following mix of cash and share-based compensation to the non-executive directors of the Company with respect to their duties and responsibilities as directors of the Company for the 2026 financial year which will end on December 31, 2026:

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;***Cash Compensation*** | &nbsp;&nbsp;***Share-based Compensation (Value at grant date)*** | &nbsp;&nbsp;***Total Annual Compensation<br> (Cash + Share-based)*** |
| &nbsp;&nbsp;*USD 100,000* | &nbsp;&nbsp;*USD 150,000* | &nbsp;&nbsp;*USD 250,000* |

---

The share-based compensation shall be granted in the form of restricted stock units under the terms of the Company's 2024 Equity Incentive Plan. Both the cash and share-based compensation shall be paid in quarterly installments, with share-based compensation vesting on the first anniversary of the grant date. The vesting of granted awards shall not be subject to continued service on the Company's Board of Directors and shall not be tied to performance requirements.

In the event a non-executive director steps down from the Board of Directors at any time before the next annual general meeting, any quarterly payments and/or grants due after his or her departure shall be forfeited and the Company shall be entitled to offer them to a replacement non-executive director.

The Compensation Committee reviews the non-executive board members' level of compensation by taking into account the non-executive compensation practices of the industry and other peer companies, among other factors. The Compensation Committee believes that the mix of cash and share-based compensation proposed is reasonable and within the range of compensation arrangements of non-executive board members of other public technology companies, and, therefore, the recommendation of the Compensation Committee is to approve such mix for the fiscal year ending on December 31, 2026.

After careful review and consideration, the Compensation Committee also deems it advisable and proposes to maintain the same additional share-based compensation paid to Mrs. Rottenberg, for her role as lead independent director for the financial year 2025, for her role as lead independent director for the financial year 2026, in the form of an extra number of restricted stock units under the terms of the Company's 2024 Equity Incentive Plan, with a value at grant date of USD 150,000, to be granted in quarterly installments, and vesting on the first anniversary of the grant date. The vesting of these awards will be subject to the continuous service of Mrs. Rottenberg in her role as lead independent director through the vesting date.

The Compensation Committee believes that the proposed additional compensation is reasonable considering the significant responsibilities and duties undertaken by the lead independent director (including consulting and agreeing with the chairman on the frequency and schedule of Board of Directors and Board of Directors committees meetings; coordinating and presiding over all meetings of the Board of Directors at which the Chairman is not present and over all meetings and executive sessions of independent directors; and serving as the principal liaison between the independent directors and the Chairman/Chief Executive Officer, and the senior management), and the level of commitment expected from such role. The Compensation Committee also believes that such additional compensation is necessary to attract, motivate, and retain qualified individuals to serve in the role of lead independent director of a company such as Globant. Further, the total compensation of Mrs. Rottenberg reflects her leadership role among the non-executive directors, and the Compensation Committee believes that it is consistent with the average total compensation of the top paid non-executive directors of other public technology companies.

With respect to the share-based compensation, the Compensation Committee has also considered that U.S. companies commonly issue share-based compensation to non-executive directors, and the Company, which is listed on the New York Stock Exchange, has adopted this approach to better reflect U.S. market practice.

Further, the Compensation Committee believes that payment of a portion of the compensation to the Company's non-executive directors in the form of restricted stock units not only serves as a recruiting and incentive instrument, but also acts to strengthen the alignment of the interests of the non-executive directors and the interests of the Company's shareholders, by motivating participants to focus on shareholder value and returns.

The Compensation Committee notes that the proposed cash and share-based compensation covers the full amount of cash and share-based compensation to be paid to non-executive directors (including for their service on any of the Board of Directors' committees) and to the lead independent director for the period commencing after the approval thereof by the shareholders at the annual general meeting of shareholders, and up to the date of the annual general meeting of shareholders to be held in 2027 to resolve on the approval of the annual accounts of the Company for the financial year ending on December 31, 2026.

The Compensation Committee also notes that the average total compensation proposed for Globant's non-executive directors, including the additional compensation proposed for Mrs. Rottenberg, remains the same as the amounts paid to the Company's non-executive directors and the lead independent director for the 2024 financial year, and below the average total compensation of non-executive directors of other peer companies.

None of the Company's executive officers, who are also members of the Board of Directors, shall receive cash or share-based compensation for their service as a member of the Board of Directors and, under Luxembourg Laws, executive compensation not related to directors' duties is not subject to shareholder approval. As a consequence, shareholder approval is not being sought in that respect.

After careful review and consideration, the Compensation Committee recommends a vote **FOR** the proposed cash and share-based compensation to the non-executive members of the Board of Directors and the lead independent director for the financial year ending on December 31, 2026.

**7. Appointment of PricewaterhouseCoopers, *Société coopérative*, as independent auditor for the annual accounts and the EU IFRS consolidated accounts of the Company for the financial year ending on December 31, 2026.**

Draft resolution (Resolution VI)

*"The general meeting renews the mandate of PricewaterhouseCoopers, Société coopérative, as independent auditor for the annual accounts and the EU IFRS consolidated accounts of the Company for the financial year ending on December 31, 2026, and for a term to expire on the date of the annual general meeting of shareholders of the Company to be held in 2027."*

<u>Recommendation</u>

In accordance with the charter of the Audit Committee adopted by the Board of Directors the purpose of the Audit Committee is, among other tasks, to assist with the Board of Directors' oversight of the Company's accounting and financial reporting processes and the audits of the Company's financial statements. The Audit Committee is responsible for recommendations to the general meeting of shareholders of the Company regarding the appointment, replacement, compensation, evaluation and oversight of the work of the independent auditors to be retained to audit the annual financial statements of the Company and review the quarterly financial statements of the Company.

During the fiscal year ending on December 31, 2025, PricewaterhouseCoopers, *Société cooperative* did not receive fees for non-audit services.

The Audit Committee recommends a vote **FOR** the re-appointment of PricewaterhouseCoopers, *Société coopérative,* as independent auditor for the annual accounts and the EU IFRS consolidated accounts of the Company for the financial year ending on December 31, 2026 and for a term to expire on the date of the annual general meeting of shareholders of the Company to be held in 2027.

**8. Appointment of Price Waterhouse & Co. S.R.L. as independent auditor for the IFRS consolidated accounts of the Company for the financial year ending on December 31, 2026.**

Draft resolution (Resolution VII)

*"The general meeting appoints Price Waterhouse & Co. S.R.L., as independent auditor for the IFRS consolidated accounts of the Company for the financial year ending on December 31, 2026 and for a term to expire on the date of the annual general meeting of shareholders of the Company to be held in 2027."*

<u>Recommendation</u>

In accordance with the charter of the Audit Committee adopted by the Board of Directors the purpose of the Audit Committee is, among other tasks, to assist with the Board of Directors' oversight of the Company's accounting and financial reporting processes and the audits of the Company's financial statements. The Audit Committee is responsible for recommendations to the general meeting of shareholders of the Company regarding the appointment, replacement, compensation, evaluation and oversight of the work of the independent auditors to be retained to audit the annual financial statements of the Company and review the quarterly financial statements of the Company.

During the fiscal year ending on December 31, 2025, Price Waterhouse & Co. S.R.L. did not receive fees for non-audit services.

The Audit Committee of the Company recommends a vote **FOR** the re-appointment of Price Waterhouse & Co. S.R.L. as independent auditor for the IFRS consolidated accounts of the Company for the financial year ending on December 31, 2026 and for a term to expire on the date of the annual general meeting of shareholders of the Company to be held in 2027.

**9. Re-appointment of Mrs. Linda Rottenberg as member of the Board of Directors for a term ending on the date of the Annual General Meeting of Shareholders of the Company to be held in 2029.**

Draft resolution (Resolution VIII)

*"The general meeting re-appoints Mrs. Linda Rottenberg as member of the Board of Directors of the Company for a term to expire on the date of the annual general meeting of shareholders of the Company to be held in 2029."*

<u>Recommendation</u>

The directors are appointed by the general meeting of shareholders for a period of up to four (4) years; <u>provided</u>, <u>however</u>, that directors shall be elected on a staggered basis, with one third (1/3) of the directors being elected each year and; <u>provided further</u>, that such term may be exceeded by a period up to the annual general meeting held following the fourth anniversary of the appointment. The directors shall be eligible for re-election indefinitely.

In accordance with the charter of the Corporate Governance and Nominating Committee adopted by the Board of Directors, the Corporate Governance and Nominating Committee is tasked with, among other functions, (a) identifying and evaluating individuals believed to be qualified as candidates to serve on the Board of Directors and selecting, or recommending that the Board of Directors select such candidates for all directorships to be filled by the Board of Directors or by the shareholders at an annual or special meeting, (b) reviewing and making recommendations to the full Board of Directors, or determining whether members of the Board of Directors should stand for re-election, (c) conducting all necessary and appropriate inquiries into the backgrounds and qualifications of possible candidates, (d) evaluating candidates for nomination to the Board of Directors, including those recommended by shareholders, and (e) reviewing and making recommendations, as it deems appropriate, regarding the composition and size of the Board of Directors in order to ensure that the Board of Directors has the requisite expertise and its membership consists of persons with sufficiently diverse and independent backgrounds.

The Corporate Governance and Nominating Committee believes that Mrs. Linda Rottenberg is qualified to serve on our Board of Directors due to her knowledge and experience in the technology industry and experience serving as a director of other companies.

<u>Linda Rottenberg</u>

Ms. Rottenberg has served as a member of our board of directors since 2017 and served as a member and chairman of Globant's Corporate Governance and Nominating Committee from 2020 to September 2023. Since October 3, 2023 and September 30, 2023, respectively, Ms. Rottenberg has served as Lead Independent Director and a member of Globant's Audit Committee. Ms. Rottenberg previously served as a member of the Audit Committee from May 9, 2017 through August 2021. Named "Innovator for the 21st Century" (TIME) and one of "America's Best Leaders" (U.S. News), Ms. Rottenberg is cofounder and CEO of Endeavor, the leading global community of, by, and for high-impact entrepreneurs. Operating in more than 40 markets spanning the globe, Endeavor identifies, scales up, and co-invests in the most innovative, rapidly growing businesses in emerging and underserved markets. Ms. Rottenberg also serves as President of Endeavor Catalyst, the rules-based investment arm of Endeavor with $500M in assets under management across four funds. Launched in 2012, Endeavor Catalyst has invested in 300+ companies under Ms. Rottenberg's leadership. The portfolio comprises 24 exited investments and 50 "unicorn" companies valued at over $1B+. Ms. Rottenberg currently serves as a director in OLO (NYSE: OLO), a top SaaS-based food ordering platform. She also serves on the board of Pershing Square SPARC Holdings. She formerly served as a director of ZAYO, a global bandwidth infrastructure company. She is also a member of YPO, World Economic Forum, Anchor Fund Advisory Board, Yale Ventures Advisory Board, and Vice Chair of Yale President's Council on International Activities. Author of the New York Times bestselling book, CRAZY IS A COMPLIMENT, and accomplished public speaker, Ms. Rottenberg has been the subject of six Harvard Business School case studies and one Stanford GSB case study. Other honors include the Silicon Valley Forum Visionary Award; Heinz Award for Technology, the Economy, and Employment; Babson College Honorary Doctorate; and the Yale Law School Award of Merit. A graduate of Harvard College and Yale Law School.

After careful review of the merits of Mrs. Rottenberg, the Corporate Governance and Nominating Committee recommends a vote **FOR** the re-appointment of Mrs. Rottenberg as a director of the Company for a term to expire on the date of the annual general meeting of shareholders of the Company to be held in 2029.

**10. Re-appointment of Mr. Martín Gonzalo Umaran as member of the Board of Directors for a term ending on the date of the Annual General Meeting of Shareholders of the Company to be held in 2029.**

Draft resolution (Resolution IX)

*"The general meeting appoints Mr. Martín Gonzalo Umaran as member of the Board of Directors of the Company for a term to expire on the date of the annual general meeting of shareholders of the Company to be held in 2029."*

<u>Recommendation</u>

The directors are appointed by the general meeting of shareholders for a period of up to four (4) years; <u>provided</u>, <u>however</u>, that directors shall be elected on a staggered basis, with one third (1/3) of the directors being elected each year and; <u>provided further</u>, that such term may be exceeded by a period up to the annual general meeting held following the fourth anniversary of the appointment. The directors shall be eligible for re-election indefinitely.

In accordance with the charter of the Corporate Governance and Nominating Committee adopted by the Board of Directors, the Corporate Governance and Nominating Committee is tasked with, among other functions, (a) identifying and evaluating individuals believed to be qualified as candidates to serve on the Board of Directors and selecting, or recommending that the Board of Directors select such candidates for all directorships to be filled by the Board of Directors or by the shareholders at an annual or special meeting, (b) reviewing and making recommendations to the full Board of Directors, or determining whether members of the Board of Directors should stand for re-election, (c) conducting all necessary and appropriate inquiries into the backgrounds and qualifications of possible candidates, (d) evaluating candidates for nomination to the Board of Directors, including those recommended by shareholders and (e) reviewing and making recommendations, as it deems appropriate, regarding the composition and size of the Board of Directors in order to ensure that the Board of Directors has the requisite expertise and its membership consists of persons with sufficiently diverse and independent backgrounds.

The Corporate Governance and Nominating Committee believes that Mr. Umaran is qualified to serve on our Board of Directors due to his intimate familiarity with our Company and his perspective, experience, and operational expertise in the technology services industry that he has developed during his career as a co-founder of our Company.

<u>Martín Gonzalo Umaran</u>

Mr. Umaran has served as a member of our board of directors since 2012 and served as Chief of Staff from 2013 to 2020. As Globant's Chief of Staff, Mr. Umaran was responsible for coordinating our back-office activities, supporting executives in daily projects and acting as a liaison to our senior management. Since 2008, he has been responsible for our mergers and acquisitions processes and strategic initiatives. From 2005 to 2012, Mr. Umaran served as Globant's Chief Operations Officer and Chief Corporate Business Officer, in charge of managing our delivery teams and projects. In 2022, Mr. Umaran was appointed as Chief Corporate Development Officer, responsible to incorporate other organizations into the Company as part of its global growth strategy. He has also been named President for EMEA, working side by side with our team in the region to achieve Globant's growth plans. Together with his three Globant co-founders, Mr. Umaran was selected as an Endeavor Entrepreneur in 2005. Mr. Umaran holds a degree in mechanical engineering from Universidad Nacional de La Plata (UNLP) and a Masters in Business Administration from IDEA.

After careful review of the merits of Mr. Umaran, the Corporate Governance and Nominating Committee recommends a vote **FOR** the appointment of Mr. Umaran as a director of the Company for a term to expire on the date of the annual general meeting of shareholders of the Company to be held in 2029.

**11. Re-appointment of Mr. Guibert Andrés Englebienne as member of the Board of Directors for a term ending on the date of the Annual General Meeting of Shareholders of the Company to be held in 2029.**

Draft resolution (Resolution X)

*"The general meeting appoints Mr. Englebienne as member of the Board of Directors of the Company for a term to expire on the date of the annual general meeting of shareholders of the Company to be held in 2029."*

<u>Recommendation</u>

The directors are appointed by the general meeting of shareholders for a period of up to four (4) years; <u>provided</u>, <u>however</u>, that directors shall be elected on a staggered basis, with one third (1/3) of the directors being elected each year and; <u>provided further</u>, that such term may be exceeded by a period up to the annual general meeting held following the fourth anniversary of the appointment. The directors shall be eligible for re-election indefinitely.

In accordance with the charter of the Corporate Governance and Nominating Committee adopted by the Board of Directors, the Corporate Governance and Nominating Committee is tasked with, among other functions, (a) identifying and evaluating individuals believed to be qualified as candidates to serve on the Board of Directors and selecting, or recommending that the Board of Directors select such candidates for all directorships to be filled by the Board of Directors or by the shareholders at an annual or special meeting, (b) reviewing and making recommendations to the full Board of Directors, or determining whether members of the Board of Directors should stand for re-election, (c) conducting all necessary and appropriate inquiries into the backgrounds and qualifications of possible candidates, (d) evaluating candidates for nomination to the Board of Directors, including those recommended by shareholders and (e) reviewing and making recommendations, as it deems appropriate, regarding the composition and size of the Board of Directors in order to ensure that the Board of Directors has the requisite expertise and its membership consists of persons with sufficiently diverse and independent backgrounds.

The Corporate Governance and Nominating Committee believes that Mr. Englebienne is qualified to serve on our Board due to his intimate familiarity with our Company and his perspective, experience, and operational expertise in the technology services industry that he has developed during his career as our co-founder and executive officer.

<u>Guibert Andrés Englebienne</u>

Mr. Englebienne has served as a member of our board of directors since 2003. In 2021, Mr. Englebienne became President of Globant X and Globant Ventures to help drive the success of these initiatives. He also was appointed President for Latin America, a role to provide strategic advice to our regional leadership. Mr. Englebienne previously served as our Chief Technology Officer from 2003 to 2021. He is one of Globant's co-founders. Prior to co-founding Globant, Mr. Englebienne worked as a scientific researcher at IBM and, later, as head of technology for CallNow.com Inc. As Globant's Chief Technology Officer, he oversees the technological development of Globant's diverse Studios, each a deep pocket of expertise with a focus on incorporating the latest trends to bring solutions to global companies. Together with his three Globant co-founders, Mr. Englebienne was selected as an Endeavor Entrepreneur in 2005. In addition to his responsibilities at Globant, Mr. Englebienne is President of Endeavor Argentina. In 2011, he was included in Globalization Today's "Powerful 25" list. Mr. Englebienne holds a bachelor's degree in Computer Science and Software Engineering from the Universidad Nacional del Centro de la Provincia de Buenos Aires in Argentina.

After careful review of the merits of Mr. Englebienne, the Corporate Governance and Nominating Committee recommends a vote **FOR** the re-appointment of Mr. Englebienne as a director of the Company for a term to expire on the date of the annual general meeting of shareholders of the Company to be held in 2029.

**Board of Directors overview**

The Corporate Governance and Nominating Committee believes that having directors with complementary skills, experience and expertise is important to meeting its oversight responsibilities.

Our Corporate Governance and Nominating Committee adopted the Board of Directors Skill and Experience Matrix as an additional tool to improve the evaluation process of new Board of Directors nominees. The table below summarizes the most relevant key qualifications, skills and attributes of the members of the Board of Directors, including those whose mandate will continue after the Annual General Meeting of Shareholders of the Company:

![](tm2610084d1_ex99-1img002.jpg)

**Board of Directors Committees overview**

The chart below describes the current composition of the Board of Directors committees. Please note that the composition of these committees will be reviewed and may change following the conclusion of the AGM:

![](tm2610084d1_ex99-1img003.jpg)

\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*

![](tm2610084d1_ex99-1img001.jpg)

The Annual General Meeting of Shareholders (the "**Meeting**") shall be conducted in conformity with the voting requirements of the Companies Law, and the Company's Articles of Association.

Each of the items to be voted on the Annual General Meeting will be passed by a simple majority of the votes validly cast, irrespective of the number of common shares present or represented at the Annual General Meeting.

**<u>Right to Amend the Content of the Agenda</u>**

Pursuant to the Company's Articles of Association shareholders holding at least five percent (5%) of the Company's issued share capital may request the adjunction of one or several items to the agenda of the Meeting, provided that the request is accompanied by a justification of or draft resolution(s). Such request and justification of or draft resolution(s) must be received at the Company's registered office by registered letter (to the attention of the Board of Directors, 37A, avenue J.F. Kennedy L-1855 Luxembourg) or by e-mail (to: gcoffice@globant.com) at the latest on the twenty-second (22nd) day prior to the date of the relevant Meeting, *i.e.* on April 6, 2026. The request shall be further accompanied by a certificate evidencing the shareholding of such shareholder(s) on the Record Date (as defined below) and the mailing address or e-mail address of the shareholder which the Company may use in order to deliver the acknowledgment of receipt of such request.

**<u>Right to Participate in the Meeting</u>**

Any shareholder who holds one or more common shares(s) of the Company on March 27, 2026, at 24.00 (midnight) Luxembourg time (the "**Record Date**") and registers for the Meeting (please see below section "*Procedures for Attending the Meeting, Voting by Proxy and/or Submitting Votes*") and provides the certificate specified below, shall be admitted to the Meeting and may attend the Meeting in person or vote by proxy.

**<u>Documents</u>**

Documents and information required by law, including, amongst others, copies of the consolidated accounts of the Company for the financial year ended December 31, 2025 and the Company's annual accounts for the financial year ended December 31, 2025, together with the relevant management reports and audit reports, are made available for an uninterrupted period between the date of the publication of this convening notice and the date of the Meeting, in the investors section on the Company's website, www.globant.com. They may also be obtained free of charge at the Company's registered office in Luxembourg. Upon request to gcoffice@globant.com copies of the afore-mentioned documents will be mailed to the shareholders.

**<u>Procedures for Attending the Meeting, Voting by Proxy and/or Submitting Votes</u>**

All shareholders wishing to participate in person or by voting through a proxyholder in the Meeting shall notify the Company thereof at the latest on April 22, 2026, in writing by mail or by e-mail.

Any shareholder and/or proxy holder participating in the Meeting in person shall carry proof of identity at the Meeting.

Shareholders (whose common shares are held in book-entry form through the operator of a securities settlement system or with a professional depositary or sub-depositary designated by such depositary) should request from their operator or depositary or sub-depositary a certificate certifying the number of common shares recorded in their account on the Record Date.

In addition to the aforementioned notification, to participate and vote in the Meeting, such shareholders (whose common shares are held in book-entry form through the operator of a securities settlement system or with a professional depositary or sub-depositary designated by such depositary) shall submit a copy of the certificate via their custodian bank by mail or by e-mail to the Company at the latest on April 22, 2026, at 24.00 (midnight) Luxembourg Time.

- <u>Attending the Meeting</u>

If you wish to attend the Meeting you must notify the Company thereof no later than on April 22, 2026. Shareholders need not be present at the Meeting in person, they may appoint a proxyholder. Such appointment shall be made in writing, and it shall be notified to the Company no later than 24.00 (midnight) Luxembourg Time on April 22, 2026, at the address indicated below.

In the case of common shares owned by a corporation or any other legal entity, individuals representing such entity who wish to attend the Meeting in person and vote at the Meeting, on behalf of such entity must present evidence of their authority to attend and vote at the Meeting, by means of a proper document (such as a special power-of-attorney) issued by the entity represented. A copy of such power-of-attorney or other proper document should be filed not later than 24.00 (midnight) Luxembourg Time on April 22, 2026, at the address indicated below.

Address for filing powers-of-attorney:

Globant S.A.

37A, Avenue J.F. Kennedy,

L-1855 Luxembourg

R.C.S. Luxembourg B 173727

Attention: Pablo Rojo

Email: gcoffice@globant.com

- <u>Voting by Ballot Paper.</u>

To vote by ballot paper, holders of common shares (other than through a brokerage account) must complete ballot papers. If you hold your shares in your name directly at the books and records of the Company's transfer agent, Equiniti Trust Company, LLC ("**Equiniti**"), you must complete a ballot paper in order to vote your common shares. In order for the votes to count, ballot papers must be received by Equiniti at the return address or email indicated on the ballot papers, no later than 24.00 (midnight) Luxembourg Time on April 22, 2026.

<u>Submitting Votes through a Broker.</u>

If you hold your shares through a brokerage account, please contact your broker to receive information on how you may vote your shares. In order for the votes to count, votes shall be received by Equiniti before 24.00 (midnight) Luxembourg Time on April 22, 2026.

Yours faithfully,

For the Board of Directors of the Company

---

| |
|:---|
| /s/ Martin Migoya |
| Martin Migoya |
| Title: Chairman of the Board of Directors |

---

\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](tm2610084d1_ex99-1img004.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0 ------------------ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ---------------- 14475 GLOBANT S.A. 37A, Avenue J.F. Kennedy, L-1855, Luxembourg RCS Luxembourg: B 173727 The undersigned hereby appoints the Chairman of the General Meeting as proxy, with full power of substitution, to represent and vote as designated on the reverse side, all of the common shares of Globant S.A. (the "Company") held of record by the undersigned at 24 o'clock Luxembourg Time on March 27, 2026, at the Annual General Meeting of Shareholders to be held at the Company's registered office on April 28, 2026, and at any adjournments or postponements thereof. This proxy is governed by Luxembourg law. Any disputes arising out of, or in connection with, this proxy shall be submitted exclusively to the courts of the city of Luxembourg, Grand Duchy of Luxembourg. (Continued and to be signed on the reverse side) 1.1 |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](tm2610084d1_ex99-1img005.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ANNUAL GENERAL MEETING OF SHAREHOLDERS OF GLOBANT S.A. April 28, 2026 NOTICE OF INTERNET AVAILABILITY OF PROXY MATERIAL: The convening notice and proxy card are available at www.globant.com Signature of Shareholder Date: Signature of Shareholder Date: Note: Please sign exactly as your name or names appear on this Proxy. When shares are held jointly, each holder should sign. When signing as executor, administrator, attorney, trustee or guardian, please give full title as such. If the signer is a corporation, please sign full corporate name by duly authorized officer, giving full title as such. If signer is a partnership, please sign in partnership name by authorized person. To change the address on your account, please check the box at right and indicate your new address in the address space above. Please note that changes to the registered name(s) on the account may not be submitted via this method. The undersigned acknowledges receipt of the Convening Notice from the Company in advance of the execution of this proxy. 1. Presentation of the reports of the independent auditor and of the reports of the Board of Directors of the Company on the consolidated accounts for the financial year ended on December 31, 2025 and on the annual accounts of the Company for the financial year ended on December 31, 2025. 2. Approval of the consolidated accounts of the Company prepared under EU IFRS and IFRS as of and for the financial year ended December 31, 2025. 3. Approval of the Company's annual accounts under LUX GAAP as of and for the finan-cial year ended December 31, 2025. 4. Allocation of results for the financial year ended December 31, 2025. 5. Vote on discharge (quitus) of the members of the Board of Directors for the proper exercise of their mandate during the financial year ended December 31, 2025. 6. Approval of the cash and share based compensation payable to the non-executive members of the Board of Directors for the financial year ending on December 31, 2026. 7. Appointment of PricewaterhouseCoopers, Société coopérative, as independent auditor for the annual accounts and the EU IFRS consolidated accounts of the Company for the financial year ending on December 31, 2026. 8. Appointment of Price Waterhouse & Co. S.R.L. as independent auditor for the IFRS consolidated accounts of the Company for the financial year ending on December 31, 2026. 9. Re-appointment of Mrs. Linda Rottenberg as member of the Board of Directors for a term ending on the date of the Annual General Meeting of Shareholders of the Company to be held in 2029. 10. Re-appointment of Mr. Martín Gonzalo Umaran as member of the Board of Directors for a term ending on the date of the Annual General Meeting of Shareholders of the Company to be held in 2029. 11. Re-appointment of Mr. Guibert Andrés Englebienne as member of the Board of Directors for a term ending on the date of the Annual General Meeting of Shareholders of the Company to be held in 2029. If amendments or new resolutions are presented at the General Meeting, I irrevocably give the Chairman of the General Meeting the power to vote in my name and as he or she deems fit unless I mark the box below: I abstain: THE BOARD OF DIRECTORS (OR THE RELEVANT BOARD COMMITTEE) RECOMMENDS A VOTE "FOR" RESOLUTIONS 2-11 OF THE ANNUAL GENERAL MEETING. PLEASE SIGN, DATE AND RETURN PROMPTLY IN THE ENCLOSED ENVELOPE OR BY E-MAIL. PLEASE MARK YOUR VOTE IN BLUE OR BLACK INK AS SHOWN HERE x Please detach along perforated line and mail in the envelope provided. ------------------ ---------------- 042826 GO GREEN e-Consent makes it easy to go paperless. With e-Consent, you can quickly access your proxy material, statements and other eligible documents online, while reducing costs, clutter and paper waste. Enroll today via equiniti.com/us/ast-access to enjoy online access. FOR ABSTAIN MARK "X" HERE IF YOU PLAN TO ATTEND THE GENERAL MEETING. E-MAIL - Completed proxy cards may be sent via email as a PDF attachment to Equiniti Trust Company, LLC at the following email addresses: proxy@equiniti.com and admin3@equiniti.com. Please be sure to send your completed proxy card via PDF to both of the email addresses provided and to use the subject line: "Globant Proxy Card". MAIL - Sign, date and mail your proxy card in the envelope provided as soon as possible. IN PERSON - You may vote your shares in person by attending the General Meeting. (Option available only until 24 o'clock Luxembourg Time on April 22, 2026) NO VOTE REQUIRED RESOLUTIONS OF THE ANNUAL GENERAL MEETING: AGAINST |

---